SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG tit...
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
European Centre for Disease Prevention and Control
2020
|
| _version_ | 1826294780269690880 |
|---|---|
| author | Lumley, SF Eyre, DW McNaughton, AL Howarth, A Hoosdally, S Hatch, SB Kavanagh, J Chau, KK Downs, LO Cox, S Dunn, L Justice, A Wareing, S Dingle, K Rudkin, J Auckland, K Fyfe, A Bolton, J Paton, R Mentzer, AJ Jeffery, K Andersson, MI James, T Peto, TEA Marsden, BD Screaton, G Cornall, RJ Klenerman, P Ebner, D Stuart, DI Crook, DW Stoesser, N Kennedy, SH Thompson, C Gupta, S Matthews, PC |
| author_facet | Lumley, SF Eyre, DW McNaughton, AL Howarth, A Hoosdally, S Hatch, SB Kavanagh, J Chau, KK Downs, LO Cox, S Dunn, L Justice, A Wareing, S Dingle, K Rudkin, J Auckland, K Fyfe, A Bolton, J Paton, R Mentzer, AJ Jeffery, K Andersson, MI James, T Peto, TEA Marsden, BD Screaton, G Cornall, RJ Klenerman, P Ebner, D Stuart, DI Crook, DW Stoesser, N Kennedy, SH Thompson, C Gupta, S Matthews, PC |
| author_sort | Lumley, SF |
| collection | OXFORD |
| description | SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson's correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study. |
| first_indexed | 2024-03-07T03:50:57Z |
| format | Journal article |
| id | oxford-uuid:c13c0f5b-07da-4e7c-ac23-13d4e9c5bb29 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:50:57Z |
| publishDate | 2020 |
| publisher | European Centre for Disease Prevention and Control |
| record_format | dspace |
| spelling | oxford-uuid:c13c0f5b-07da-4e7c-ac23-13d4e9c5bb292022-03-27T06:00:32ZSARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c13c0f5b-07da-4e7c-ac23-13d4e9c5bb29EnglishSymplectic ElementsEuropean Centre for Disease Prevention and Control2020Lumley, SFEyre, DWMcNaughton, ALHowarth, AHoosdally, SHatch, SBKavanagh, JChau, KKDowns, LOCox, SDunn, LJustice, AWareing, SDingle, KRudkin, JAuckland, KFyfe, ABolton, JPaton, RMentzer, AJJeffery, KAndersson, MIJames, TPeto, TEAMarsden, BDScreaton, GCornall, RJKlenerman, PEbner, DStuart, DICrook, DWStoesser, NKennedy, SHThompson, CGupta, SMatthews, PCSARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson's correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study. |
| spellingShingle | Lumley, SF Eyre, DW McNaughton, AL Howarth, A Hoosdally, S Hatch, SB Kavanagh, J Chau, KK Downs, LO Cox, S Dunn, L Justice, A Wareing, S Dingle, K Rudkin, J Auckland, K Fyfe, A Bolton, J Paton, R Mentzer, AJ Jeffery, K Andersson, MI James, T Peto, TEA Marsden, BD Screaton, G Cornall, RJ Klenerman, P Ebner, D Stuart, DI Crook, DW Stoesser, N Kennedy, SH Thompson, C Gupta, S Matthews, PC SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title | SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title_full | SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title_fullStr | SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title_full_unstemmed | SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title_short | SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020 |
| title_sort | sars cov 2 antibody prevalence titres and neutralising activity in an antenatal cohort united kingdom 14 april to 15 june 2020 |
| work_keys_str_mv | AT lumleysf sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT eyredw sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT mcnaughtonal sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT howartha sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT hoosdallys sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT hatchsb sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT kavanaghj sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT chaukk sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT downslo sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT coxs sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT dunnl sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT justicea sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT wareings sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT dinglek sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT rudkinj sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT aucklandk sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT fyfea sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT boltonj sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT patonr sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT mentzeraj sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT jefferyk sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT anderssonmi sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT jamest sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT petotea sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT marsdenbd sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT screatong sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT cornallrj sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT klenermanp sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT ebnerd sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT stuartdi sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT crookdw sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT stoessern sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT kennedysh sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT thompsonc sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT guptas sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 AT matthewspc sarscov2antibodyprevalencetitresandneutralisingactivityinanantenatalcohortunitedkingdom14aprilto15june2020 |